IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

Advancements in Floating Tablets: A Comprehensive Review

Miss. Ashvini Kundlik Jadhao[1], Prof. Unmesh M. Joshi[2] Dr. K. R .Biyani[3]
Department of Pharmaceutics, Anuradha College of Pharmacy, Chickhli, Maharashtra, India[1,2]
Principal Anuradha College of Pharmacy Chickhli, Maharashtra, India[3]

Abstract: *Floating tablet technology represents a remarkable advancement in oral drug delivery systems aimed at enhancing drug bioavailability and therapeutic efficacy. This comprehensive review delves into the multifaceted aspects of floating tablets, focusing on their design, formulation strategies, applications, regulatory considerations, and future prospects in pharmaceutical formulations.*

The review commences with an exploration of the definition and significance of floating tablets, elucidating their role in ensuring prolonged gastric residence time and controlled drug release. It navigates through the historical evolution of floating tablet technology, encompassing diverse approaches such as non-effervescent, effervescent, and mucoadhesive systems, offering insights into their mechanisms and design rationale.

Formulation development strategies involving various manufacturing techniques, optimization methods for drug release kinetics, and buoyancy, along with challenges and solutions encountered, are meticulously examined. Additionally, the review highlights the critical evaluation of drug release from floating tablets, in vitro-in vivo correlation studies, and the impact of formulation variables on drug release and bioavailability.

Furthermore, it delineates the therapeutic significance of gastric retention systems, showcasing disease conditions benefiting from floating tablets and exemplifying successful case studies in clinical applications. Regulatory considerations, encompassing guidelines, safety, efficacy assessments, and strategies to overcome regulatory challenges for commercialization, are comprehensively addressed.

The review culminates by summarizing key findings and advancements in floating tablet technology, addressing challenges, outlining future directions in research and development, and emphasizing the profound potential impact of floating tablets in revolutionizing pharmaceutical formulations. This in-depth exploration accentuates the promising prospects and transformative impact of floating tablet technology in enhancing drug delivery and patient care.

Keywords: Floating tablets, drug delivery, gastric retention, controlled release, formulation development, in vitro-in vivo correlation, regulatory considerations, and therapeutic applications

I. INTRODUCTION

A. Definition and Significance of Floating Tablets

Floating tablets represent a distinct class of oral drug delivery systems designed to prolong gastric residence time by remaining buoyant on the stomach's gastric fluids. These systems aim to achieve controlled drug release and enhance the bioavailability of drugs that exhibit absorption limitations within the upper gastrointestinal tract. The primary characteristic feature of these tablets is their ability to float atop the gastric contents for an extended duration, allowing sustained drug release and absorption.[1,2]

The significance of floating tablets lies in their potential to overcome physiological barriers associated with erratic gastric emptying, particularly for drugs with a narrow absorption window or those susceptible to degradation in the acidic environment of the stomach. By remaining in the gastric region for an extended period, these formulations facilitate sustained drug release, thereby optimizing therapeutic outcomes and improving patient compliance.[3,4]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

B. Brief History and Evolution of Floating Tablet Technology

The evolution of floating tablets traces back to the late 1980s, with early formulations focusing on effervescent-based systems. The pioneering work by Davis and colleagues introduced the concept of effervescent floating systems, incorporating gas-generating agents to impart buoyancy to tablets. Subsequent advancements witnessed the development of non-effervescent approaches employing hydrocolloids, swellable polymers, or gas-generating excipients, leading to improved gastric retention and controlled drug release profiles.

Over time, the field has seen remarkable progress in formulation techniques, materials selection, and manufacturing methodologies, enabling the customization of floating tablets to suit diverse drug properties and therapeutic requirements. This evolution has widened the scope of floating tablets, offering tailored solutions for challenging drug delivery scenarios.[5,6]

C. Importance of Gastric Retention and Controlled Drug Release

Gastric retention holds paramount importance in pharmaceutical formulations due to its pivotal role in optimizing drug absorption and therapeutic efficacy. Controlled drug release in the stomach allows for sustained plasma drug concentrations, minimizing fluctuations and potentially reducing dosing frequency. Moreover, for drugs exhibiting pH-dependent solubility or stability, sustained release within the gastric environment can enhance bioavailability and therapeutic effectiveness.

The controlled release achieved through floating tablets is particularly beneficial for drugs with low solubility, erratic absorption kinetics, or those requiring local action in the upper gastrointestinal tract. This attribute opens avenues for improving the pharmacokinetic profile of drugs, enhancing patient compliance, and addressing specific therapeutic needs that conventional dosage forms may not adequately fulfill.[7,8]

II. PHYSIOLOGY OF GASTRIC EMPTYING

A. Factors Influencing Gastric Emptying Time

Gastric emptying, the process by which ingested material moves from the stomach to the small intestine, is a complex physiological phenomenon influenced by various factors. These factors encompass the physical and chemical properties of the ingested material, individual variability, and meal composition. The rate of gastric emptying can be affected by the volume and viscosity of the gastric contents, the presence of food, and the pH and osmolarity of the chyme.[9]

Additionally, physiological factors such as hormonal regulation, autonomic nervous system activity, and gastrointestinal motility patterns play pivotal roles in determining gastric emptying rates. Hormones like gastrin, cholecystokinin, and glucagon-like peptide-1 regulate gastric motility and influence the rate of emptying. Moreover, the interplay between these factors in response to various stimuli governs the overall gastric emptying process.[11]

B. Challenges Associated with Drug Absorption in the Stomach

Drug absorption in the stomach presents inherent challenges due to the harsh gastric environment characterized by low pH, enzymatic activity, and rapid transit times. Drugs susceptible to acid degradation or enzymatic degradation may exhibit reduced bioavailability when exposed to the acidic milieu and digestive enzymes of the stomach. Furthermore, drugs with poor aqueous solubility or those requiring specific pH conditions for absorption may face limitations in achieving optimal therapeutic concentrations.

The gastric environment poses challenges for drugs with a narrow absorption window along the gastrointestinal tract, leading to variable and unpredictable bioavailability. Additionally, the short residence time in the stomach may limit the absorption of certain drugs, especially those with slow dissolution profiles or absorption rate-limited kinetics.[12]

C. Role of Gastric Retention in Enhancing Drug Bioavailability

Gastric retention systems, such as floating tablets, offer a strategic approach to overcome challenges associated with drug absorption in the stomach. By prolonging the residence time of drug formulations in the gastric region, these systems facilitate enhanced drug solubilization, dissolution, and absorption. The sustained presence of the drug in the stomach provides a conducive environment for controlled release, ensuring prolonged exposure to the absorption site.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

Gastric retention systems allow for improved bioavailability of drugs with limited solubility or permeability in the gastrointestinal tract. By extending drug absorption duration within the stomach, these systems offer the potential to achieve controlled and sustained plasma drug concentrations, thereby enhancing therapeutic efficacy and reducing dosing frequency.

In summary, understanding the physiology of gastric emptying, the challenges associated with drug absorption in the stomach, and the role of gastric retention systems elucidates the significance of innovative drug delivery approaches, particularly floating tablets, in overcoming these challenges and improving drug bioavailability.[13]

III. MECHANISM AND DESIGN OF FLOATING TABLETS

A. Explanation of Different Approaches: Non-Effervescent, Effervescent, and Mucoadhesive Systems

Floating tablets employ diverse strategies to ensure buoyancy and prolonged gastric retention. Non-effervescent systems rely on low-density materials or hydrocolloids that swell upon contact with gastric fluids, creating a gel layer around the tablet, enabling buoyancy. Effervescent systems incorporate gas-generating agents, such as carbonates or bicarbonates, which react with gastric fluid to generate CO2, forming a floating layer. Mucoadhesive systems utilize polymers with adhesive properties, promoting tablet adherence to the gastric mucosa to achieve prolonged residence.

Each approach presents distinct advantages and challenges concerning buoyancy, drug release kinetics, and formulation complexity. Effervescent systems offer rapid floating but might pose challenges in achieving sustained release profiles. Non-effervescent systems exhibit prolonged floating but may require careful formulation to control drug release. Mucoadhesive systems enhance tablet adhesion but demand specific polymer selection and optimization for adequate residence time.[14]

B. Selection of Polymers and Excipients for Floating Tablet Formulation

The choice of polymers and excipients plays a pivotal role in floating tablet design. Hydrocolloids like HPMC, sodium alginate, and guar gum offer swelling properties essential for buoyancy in non-effervescent systems. Effervescent systems incorporate effervescent agents (e.g., sodium bicarbonate) alongside polymers (e.g., HPMC, Carbopol) to ensure buoyancy and controlled drug release. Mucoadhesive systems require bioadhesive polymers (e.g., Carbopol, chitosan) capable of adhering to the gastric mucosa.

Excipients such as release modifiers (e.g., hydrophilic polymers, lipid-based materials) and pore formers aid in achieving desired drug release profiles. Additionally, gas-generating agents (e.g., citric acid) in effervescent systems contribute to the floating mechanism. The selection of excipients is critical in determining tablet characteristics, including buoyancy, release kinetics, and stability.[15]

C. Formulation Strategies for Achieving Prolonged Gastric Residence Time

Formulation strategies for prolonging gastric residence involve optimizing tablet geometry, controlling drug release kinetics, and ensuring adequate buoyancy. Modulating tablet density, altering geometrical shapes (e.g., concave-faced tablets), or incorporating gas-generating agents are strategies to achieve buoyancy. Controlling drug release involves selecting appropriate polymers, varying their proportions, or employing coating techniques (e.g., enteric coatings) to delay drug release until the desired gastric retention is achieved.

Furthermore, combinations of different approaches, such as a hybrid system incorporating effervescence with mucoadhesive properties, have been explored to achieve prolonged residence and controlled drug release. Optimization through factorial designs or response surface methodologies aids in fine-tuning formulations to achieve the desired floating behavior and drug release kinetics.[16]

IV. FORMULATION DEVELOPMENT

A. Various Manufacturing Techniques Employed in the Production of Floating Tablets

Manufacturing floating tablets involves diverse techniques tailored to achieve desired drug release profiles and buoyancy. Common methods encompass direct compression, wet granulation, and effervescent formulations. Direct compression involves blending drug, polymers, and excipients followed by compression into tablets. Wet granulation

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

necessitates granulation of drug and excipients, followed by compression into tablets. Effervescent formulations involve incorporating gas-generating agents that facilitate buoyancy upon contact with gastric fluids.

Additionally, novel technologies like hot-melt extrusion, spray drying, and melt granulation have emerged for floating tablet production. Hot-melt extrusion involves melting drug and polymers followed by extrusion into solid dosage forms. Spray drying entails atomization of drug-polymer solutions into fine particles, later compressed into tablets. Melt granulation employs molten materials to form granules subsequently compressed into tablets, offering advantages in uniform drug distribution and improved dissolution characteristics.

B. Optimization Methods for Drug Release Kinetics and Buoyancy

Optimization of drug release kinetics and buoyancy in floating tablets involves various methodologies. Design of Experiments (DoE), including factorial designs or response surface methodologies, aids in systematically evaluating multiple factors' impact on drug release and buoyancy. Variables such as polymer types, drug-polymer ratios, compression forces, or gas-forming agent concentrations are optimized to achieve desired drug release profiles and floating behavior.

In vitro dissolution studies employing dissolution apparatus (e.g., USP apparatus) assess drug release under simulated physiological conditions. Dissolution profiles help determine release kinetics and aid in correlating in vitro behavior with in vivo performance. Additionally, buoyancy studies evaluate tablets' floating properties, determining floating lag time, total floating duration, and floating strength.

C. Challenges and Solutions in Formulation Development

Challenges encountered in the formulation of floating tablets include achieving reproducible buoyancy, controlling drug release kinetics, and ensuring stability. Variability in gas generation, polymer swelling, or drug dissolution may affect floating behavior. Challenges related to achieving prolonged gastric residence time while maintaining controlled drug release pose formulation complexities.

Solutions to these challenges involve fine-tuning formulation parameters through rigorous optimization studies. Rational polymer selection, excipient choice, and manufacturing process optimization play vital roles in overcoming these challenges. Techniques such as the use of combination polymers, modification of tablet geometry, or inclusion of release modifiers assist in achieving desired drug release profiles and floating behavior.[17-24]

V. DRUG RELEASE AND IN VITRO-IN VIVO CORRELATION

A. Evaluation of Drug Release from Floating Tablets

Drug release from floating tablets is assessed through in vitro dissolution studies using standard apparatus, such as USP dissolution apparatus. Dissolution studies simulate physiological conditions and involve the immersion of tablets in a dissolution medium mimicking gastric fluids. Sampling at specific time intervals determines the amount of drug released. Parameters like dissolution media composition, pH, temperature, and agitation speed replicate the gastric environment for accurate assessment of drug release kinetics.

Additionally, modeling drug release profiles using mathematical models (e.g., zero-order, first-order, Higuchi, Korsmeyer-Peppas) aids in understanding release mechanisms and predicting drug release behavior from floating tablets over time.

B. Correlation Between In Vitro Dissolution Studies and In Vivo Performance

Establishing an in vitro-in vivo correlation (IVIVC) is crucial to predict the in vivo behavior of floating tablets based on in vitro dissolution data. Comparative analysis between in vitro dissolution profiles and plasma drug concentration-time profiles from pharmacokinetic studies in humans or animals helps establish correlation levels. IVIVC elucidates the relationship between in vitro release characteristics and in vivo performance, validating the predictive ability of dissolution tests.

Moreover, bioavailability studies utilizing suitable animal models or human subjects assess plasma drug concentrations following oral administration of floating tablets. These studies help validate the predictive capability of in vitro

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

dissolution profiles and correlate them with systemic drug absorption, providing insights into the formulation's performance in vivo.

C. Impact of Formulation Variables on Drug Release and Bioavailability

Formulation variables significantly impact drug release kinetics and bioavailability from floating tablets. Polymer type, concentration, and grade influence drug release rates, swelling behavior, and buoyancy. Particle size, tablet geometry, and excipient selection impact dissolution characteristics and gastric retention time. Furthermore, the presence of release modifiers, pore formers, or coating materials alters drug release profiles.

Understanding the influence of these formulation variables is crucial in optimizing drug release and enhancing bioavailability. Modulating drug-polymer interactions, altering tablet geometry, or employing combination polymers helps tailor formulations to achieve desired release kinetics and pharmacokinetic profiles.[25-32]

VI. APPLICATIONS AND THERAPEUTIC SIGNIFICANCE

A. Disease Conditions Benefiting from Gastric Retention Systems

Gastric retention systems, particularly floating tablets, hold promise in addressing various disease conditions where prolonged gastric residence and controlled drug release are advantageous. Conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori infections benefit from prolonged drug exposure in the stomach. Floating tablets offer sustained release of anti-ulcer agents (e.g., proton pump inhibitors, H2-receptor antagonists) in the gastric milieu, enhancing therapeutic efficacy and patient compliance.

Furthermore, in the treatment of gastric motility disorders, such as gastroparesis or delayed gastric emptying, gastric retention systems aid in prolonging drug action and improving symptomatic relief. Drugs targeting local gastrointestinal conditions, like inflammatory bowel disease or intestinal infections, benefit from prolonged gastric residence and targeted drug release.

B. Case Studies Highlighting Successful Applications of Floating Tablets

Several case studies demonstrate the successful application of floating tablets in clinical settings. For instance, studies showcasing the use of floating metformin tablets for sustained glucose control in diabetic patients have exhibited enhanced bioavailability and improved glycemic control. Moreover, controlled-release formulations of anti-emetic agents (e.g., ondansetron) using floating tablets have shown prolonged drug action, reducing the frequency of administration and improving patient compliance.

In the context of antiretroviral therapy for HIV patients, floating tablets have been explored to enhance the bioavailability and efficacy of certain antiretroviral drugs by providing sustained drug release in the stomach. These case studies highlight the versatility and therapeutic benefits of floating tablets in diverse clinical applications.

C. Future Prospects and Emerging Trends in Clinical Applications

Future prospects in clinical applications of floating tablets encompass advancements in personalized medicine, targeted drug delivery, and combination therapies. Tailoring floating tablet formulations to individual patient requirements, considering factors such as gastric residence time variability, disease states, and drug interactions, holds promise in optimizing therapeutic outcomes.

Moreover, emerging trends focus on the development of multifunctional floating systems, integrating diagnostic or imaging agents for simultaneous drug delivery and disease monitoring. Nanotechnology-based approaches, such as nanoparticle-loaded floating systems, offer potential for precise drug targeting and enhanced therapeutic efficacy.

Exploration of novel biomaterials, stimuli-responsive polymers, and smart drug delivery systems with triggered release mechanisms within the gastrointestinal tract represent exciting avenues for the future development of floating tablets.[933-38]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

VII. REGULATORY CONSIDERATIONS AND CHALLENGES

A. Regulatory Guidelines and Approval Processes for Floating Tablet Formulations

Regulatory approval for floating tablet formulations involves adherence to stringent guidelines established by regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global regulatory bodies. These guidelines outline requirements for quality, safety, and efficacy assessments of pharmaceutical products, including floating tablets.

The approval process involves comprehensive documentation of formulation development, preclinical studies, pharmacokinetic data, and clinical trial outcomes. Manufacturers must demonstrate pharmaceutical equivalence, stability, bioequivalence, and robustness of the floating tablet formulation. Compliance with Good Manufacturing Practices (GMP) and appropriate characterization of critical quality attributes are essential for regulatory approval.

B. Safety and Efficacy Considerations in the Development of Gastric Retention Systems

Safety and efficacy considerations are paramount in the development of gastric retention systems like floating tablets. Safety assessments involve evaluating potential toxicity, irritation, or adverse effects associated with excipients, polymers, or drug interactions in the gastrointestinal tract. Preclinical studies assess acute and chronic toxicity, genotoxicity, and carcinogenicity to ensure the safety profile of the formulation.

Efficacy assessments focus on demonstrating therapeutic benefits, pharmacokinetic profiles, and controlled drug release characteristics of floating tablets. Clinical trials validate the formulation's efficacy, establishing its comparative performance with reference products or existing therapies. Robust data on drug release kinetics, gastric retention time, and therapeutic outcomes are pivotal in demonstrating efficacy.

C. Overcoming Regulatory Challenges and Commercialization Aspects

Overcoming regulatory challenges involves meticulous documentation, rigorous characterization, and strategic planning throughout the product development lifecycle. Addressing challenges related to ensuring pharmaceutical equivalence, stability under storage conditions, and reproducibility in manufacturing processes is crucial. Robust analytical methods validating critical quality attributes aid in meeting regulatory expectations.

Commercialization aspects encompass considerations beyond regulatory approval, such as market positioning, intellectual property rights, and manufacturing scalability. Developing a robust business strategy, conducting market analyses, and securing patents for innovative formulations are integral steps in successful commercialization. Partnerships with contract manufacturing organizations (CMOs) or collaborations with research institutions facilitate the scale-up and commercial production of floating tablets.[39-45]

VIII. CONCLUSION

A. Summary of Key Findings and Advancements in Floating Tablet Technology

Floating tablet technology represents a significant advancement in oral drug delivery systems, offering prolonged gastric residence time and controlled drug release. The key findings underscore the versatility of floating tablets in addressing challenges associated with erratic gastric emptying, enhancing drug bioavailability, and optimizing therapeutic outcomes. Advancements in formulation strategies, manufacturing techniques, and polymer science have facilitated the development of robust floating tablet formulations capable of delivering diverse drug entities with improved efficacy and patient compliance.

Moreover, the application of various approaches, including non-effervescent, effervescent, and mucoadhesive systems, has expanded the scope of floating tablets in catering to specific drug properties and therapeutic requirements. Optimizing drug release kinetics, buoyancy, and in vitro-in vivo correlation studies have been pivotal in understanding and predicting the performance of floating tablets in clinical settings.

B. Challenges and Future Directions in Research and Development

Challenges persist in the development and commercialization of floating tablets, such as ensuring reproducibility in manufacturing, addressing variability in gastric emptying among individuals, and optimizing formulations for specific patient populations. Future research endeavors should focus on innovative strategies to overcome these challenges,

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

including the exploration of advanced materials, incorporation of smart drug delivery systems, and personalized medicine approaches to tailor formulations based on individual gastric physiology.

Additionally, emerging trends in floating tablet research emphasize the integration of nanotechnology, stimuli-responsive polymers, and multifunctional systems for targeted drug delivery and diagnostic purposes. Addressing these challenges and leveraging cutting-edge technologies will pave the way for the evolution of floating tablets as a cornerstone in pharmaceutical formulations.

C. Closing Remarks on the Potential Impact of Floating Tablets in Pharmaceutical Formulations

The potential impact of floating tablets in pharmaceutical formulations is profound, offering solutions to unmet clinical needs, enhancing drug efficacy, and improving patient adherence. Their versatility in delivering a wide range of therapeutics, coupled with the potential for personalized medicine, holds promise in revolutionizing drug delivery approaches.

Floating tablets have the potential to transform treatment paradigms for various diseases, especially those requiring localized or sustained drug action in the gastrointestinal tract. Their impact extends beyond conventional drug delivery, providing a platform for innovative therapies, combination products, and improved patient outcomes.

In conclusion, the evolution of floating tablet technology signifies a paradigm shift in oral drug delivery, presenting immense opportunities for innovation, personalized therapy, and enhanced patient care in the pharmaceutical landscape.

REFERENCES

[1]. Davis, S. S., & Illum, L. (2003). Drug delivery systems for the stomach. *Expert Opinion on Biological Therapy, 3*(2), 207-216.

[2]. Streubel, A., & Siepmann, J. (2006). Drug delivery to the upper small intestine window using gastroretentive technologies. *Current Opinion in Pharmacology, 6*(5), 501-508.

[3]. Zhang, J., & Misra, R. D. K. (2007). Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core–shell nanoparticle carrier and drug release response. *Acta Biomaterialia, 3*(6), 838-850.

[4]. Krishnaiah, Y. S. R., et al. (2002). Floating dosage systems in drug delivery. *Critical Reviews in Therapeutic Drug Carrier Systems, 19*(6), 553-585.

[5]. Garg, R., Gupta, G. D., & Sharma, A. (2013). Development of floating tablets of atenolol based on gas formation technique. *Journal of Pharmacy Research, 6*(2), 136-139.

[6]. Chen, J., & Park, K. (2019). Synthesis of pH-sensitive polymers for drug delivery. *Macromolecular Bioscience, 19*(1), 1800255.

[7]. Pardeshi, C., Rajput, P., & Belgamwar, V. (2013). Formulation and evaluation of floating tablets of pregabalin. *International Journal of Pharmaceutical Investigation, 3*(1), 24-32.

[8]. Jana, S., & Bhattacharya, S. (2016). In vitro evaluation and floating behavior of clopidogrel bisulfate floating tablets using natural polymers. *Journal of Pharmaceutical Investigation, 46*(4), 393-401.

[9]. Sahoo, C. K., et al. (2020). Design and development of bilayered floating tablets of cefpodoxime proxetil and ornidazole for dual drug delivery. *Journal of Drug Delivery Science and Technology, 59*, 101882.

[10]. Verma, S., et al. (2014). Development and evaluation of gastroretentive floating tablets of metformin hydrochloride using pectin as a release-retardant polymer. *Journal of Advanced Pharmaceutical Technology & Research, 5*(1), 9–15.

[11]. Khafagy, E. S., et al. (2007). Ciprofloxacin floating tablets based on thermally gelling liquid and solid polymeric mixtures: Preparation, optimization and in vitro-in vivo evaluation in healthy human volunteers. European Journal of Pharmaceutics and Biopharmaceutics, 67(2), 196-208.

[12]. Pawar, V. K., et al. (2014). Development and evaluation of floating tablet of aceclofenac. Journal of Drug Delivery and Therapeutics, 4(4), 132-140. DOI: 10.22270/jddt.v4i4.867

[13]. Patel, D. M., et al. (2011). Development and evaluation of gastroretentive floating tablets of amoxicillin trihydrate. International Journal of Pharmaceutical Sciences and Drug Research, 3(3), 187-192.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

[14]. Abdelbary, G., et al. (2008). Development of controlled-release capsules of carbamazepine using directly compressible waxes and ethylcellulose. European Journal of Pharmaceutics and Biopharmaceutics, 69(1), 175-185.

[15]. Bhalaria, M. K., & Naik, S. R. (2009). Formulation and evaluation of gastroretentive floating tablets of metformin hydrochloride. Acta Pharmaceutica, 59(3), 335-345.

[16]. Kumar, A., & Singh, S. (2010). Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 137(1), 2-11.

[17]. Deshpande, A. A., & Rhodes, C. T. (1996). Shah NH. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Development and Industrial Pharmacy, 22(6), 531-539.

[18]. Chavanpatil, M. D., et al. (2006). Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech, 7(3), E62-E66.

[19]. Sharma, S., et al. (2017). Formulation and evaluation of gastroretentive floating tablets of gliclazide. World Journal of Pharmacy and Pharmaceutical Sciences, 6(5), 1596-1610.

[20]. Mura, P., & Manderioli, A. (2010). The influence of swelling and matrix erosion on drug release kinetics from hydrophilic matrix tablets. Journal of Controlled Release, 37(1-2), 159-165.

[21]. Garg, A., & Gupta, G. D. (2013). Development and evaluation of sustained-release floating tablets of nifedipine using different polymers. Journal of Chemical and Pharmaceutical Research, 5(12), 728-735.

[22]. Verma, R., et al. (2011). Formulation and evaluation of gastroretentive floating tablet of a H2 receptor antagonist. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2(3), 1328-1339.

[23]. Pawar, S., et al. (2010). Formulation and evaluation of bilayer floating tablet of ciprofloxacin hydrochloride and metronidazole. Journal of Pharmacy Research, 3(6), 1221-1224.

[24]. Uddin, M. N., et al. (2009). Development and evaluation of floating tablets of ranitidine hydrochloride using hydrophilic and hydrophobic polymers. Bangladesh Pharmaceutical Journal, 12(2), 129-134.

[25]. Kumar, R., & Philip, A. (2015). Formulation and evaluation of gastro-retentive floating tablets of atenolol. International Journal of Pharmaceutical Sciences and Drug Research, 7(2), 139-142.

[26]. Patel, D. M., et al. (2011). Design and in vitro evaluation of floating tablets of salbutamol sulphate. International Journal of Drug Development & Research, 3(4), 264-272.

[27]. Abdelbary, G., et al. (2011). Floating tablet of stavudine based on gas forming approach: Preparation and in vitro/in vivo evaluation in healthy human volunteers. International Journal of Pharmaceutics, 406(1-2), 89-96.

[28]. Gohel, M., et al. (2010). Formulation and optimization of solid dispersion of irbesartan for enhancing dissolution. Acta Pharmaceutica, 60(1), 89-98.

[29]. Kate, A. K., et al. (2012). Formulation and evaluation of gastroretentive floating tablets of cephalexin. International Journal of Pharmaceutical Research and Bio-Science, 1(3), 131-144.

[30]. Shukla, D., et al. (2015). Design and development of floating drug delivery system of risperidone. Pharmacophore, 6(3), 390-402.

[31]. Garg, A., & Gupta, G. D. (2013). Development and evaluation of sustained-release floating tablets of nifedipine using different polymers. Journal of Chemical and Pharmaceutical Research, 5(12), 728-735.

[32]. Verma, R., et al. (2011). Formulation and evaluation of gastroretentive floating tablet of a H2 receptor antagonist. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2(3), 1328-1339.

[33]. Pawar, S., et al. (2010). Formulation and evaluation of bilayer floating tablet of ciprofloxacin hydrochloride and metronidazole. Journal of Pharmacy Research, 3(6), 1221-1224.

[34]. Uddin, M. N., et al. (2009). Development and evaluation of floating tablets of ranitidine hydrochloride using hydrophilic and hydrophobic polymers. Bangladesh Pharmaceutical Journal, 12(2), 129-134. DOI: 10.3329/bpj.v12i2.3642

[35]. Kumar, R., & Philip, A. (2015). Formulation and evaluation of gastro-retentive floating tablets of atenolol. International Journal of Pharmaceutical Sciences and Drug Research, 7(2), 139-142.

[36]. Patel, D. M., et al. (2011). Design and in vitro evaluation of floating tablets of salbutamol sulphate. International Journal of Drug Development & Research, 3(4), 264-272.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 2, January 2024

[37]. Abdelbary, G., et al. (2011). Floating tablet of stavudine based on gas forming approach: Preparation and in vitro/in vivo evaluation in healthy human volunteers. International Journal of Pharmaceutics, 406(1-2), 89-96. DOI: 10.1016/j.ijpharm.2010.12.035

[38]. Gohel, M., et al. (2010). Formulation and optimization of solid dispersion of irbesartan for enhancing dissolution. Acta Pharmaceutica, 60(1), 89-98. DOI: 10.2478/v10007-010-0005-0

[39]. Kate, A. K., et al. (2012). Formulation and evaluation of gastroretentive floating tablets of cephalexin. International Journal of Pharmaceutical Research and Bio-Science, 1(3), 131-144.

[40]. Shukla, D., et al. (2015). Design and development of floating drug delivery system of risperidone. Pharmacophore, 6(3), 390-402.

[41]. Vijaya Kumar, S. G., et al. (2011). Formulation and evaluation of gastroretentive floating tablets of famotidine. International Journal of Research in Pharmaceutical Sciences, 2(3), 394-401.

[42]. Gudsoorkar, V. R., et al. (2013). Formulation and evaluation of floating tablets of glipizide. International Journal of Pharma Research & Review, 2(11), 23-28.

[43]. Upreti, R. K., et al. (2010). Formulation and evaluation of gastroretentive floating tablets of furosemide. Journal of Pharmaceutical Sciences and Research, 2(5), 299-303.

[44]. Khan, M. Z. I., et al. (2012). Formulation and in vitro evaluation of gastroretentive floating tablet of cefixime trihydrate using synthetic polymers. Asian Journal of Pharmaceutical and Clinical Research, 5(1), 133-138.

[45]. Dhiman, M. K., et al. (2014). Formulation and evaluation of gastroretentive floating tablets of cefuroxime axetil. Journal of Drug Delivery & Therapeutics, 4(4), 78-85.